Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

This study is looking for adults aged 18 or over who have advanced cancers that have spread or can't be cured by standard treatments. Your cancer must also have a specific genetic change called KRAS G12C. This includes certain types of lung, bowel, or pancreatic cancer.

To join, your cancer must have been treated before. For some specific cancers like non-small cell lung cancer, you would need to have already tried certain common treatments like immunotherapy, chemotherapy, and other KRAS G12C drugs. However, for other solid cancers, you might be eligible even if you haven't tried a KRAS G12C drug before.

There are also some important health checks, like having good general health and normal organ function. You wouldn't be able to join if you have cancer that started in your brain, or if your cancer has spread to your brain and is causing active problems. Also, if you've had major surgery recently or have certain stomach or bowel conditions that might affect how the medicine is absorbed, you might not be suitable.

If you decide to take part, you'll be given either one of the new medicines or a combination of both. You will have regular hospital visits for check-ups, blood tests, and scans to see how you're responding and to monitor any side effects. The study involves different stages, starting with safely finding the right dose, then continuing to assess the medicine's effects. Your medical team will explain the full schedule of appointments and tests. The total time you'd be in the study can vary depending on your response to the treatment, but you can choose to leave the study at any time.